

**Tristel plc**  
**("Tristel" or the "Company")**

**Exercise of Share Options and Total Voting Rights**

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has issued and allotted a further 5,000 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following another exercise of options by employees of the Company.

Application has been made to the London Stock Exchange for the additional 5,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 16 October 2025, together with the 15,000 new ordinary shares to be admitted to trading on AIM pursuant to the employee exercise of options announced on 9 October.

**Total Voting Rights**

After Admission, the total number of Ordinary Shares in issue will be 47,745,043 and the total number of voting rights will therefore be 47,745,043. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

**For further information please contact:**

**Tristel plc**  
Matt Sassone, Chief Executive Officer  
Anna Wasyl, Chief Financial Officer

Via Walbrook PR  
[www.investors.tristel.com](http://www.investors.tristel.com)

**Walbrook PR Ltd**  
Paul McManus / Lianne Applegarth / Anna Dunphy

Tel: 020 7933 8780 or [tristel@walbrookpr.com](mailto:tristel@walbrookpr.com)  
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

**Cavendish Capital Markets Ltd**  
Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)  
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

Tel: 020 7220 0500



**About Tristel plc**

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO<sub>2</sub>) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the [Tristel](#) brand, and under the [Cache](#) brand provides products for sporidical surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEMJBPTMTABMTA